Acquired resistance to cancer immunotherapy

doi:10.1007/s00281-018-0692-y

Review

. 2019 Jan;41(1):31-40.

doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.

Acquired resistance to cancer immunotherapy

Arianna Draghi¹, Christopher Aled Chamberlain¹, Andrew Furness², Marco Donia^{3

4}

Affiliations

¹ Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark.
² Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
³ Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark. marco.donia@regionh.dk.
⁴ Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. marco.donia@regionh.dk.

PMID: 29968044
DOI: 10.1007/s00281-018-0692-y

Review

Acquired resistance to cancer immunotherapy

Arianna Draghi et al. Semin Immunopathol. 2019 Jan.

. 2019 Jan;41(1):31-40.

doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.

Authors

Arianna Draghi¹, Christopher Aled Chamberlain¹, Andrew Furness², Marco Donia^{3

4}

Affiliations

¹ Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark.
² Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
³ Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark. marco.donia@regionh.dk.
⁴ Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. marco.donia@regionh.dk.

PMID: 29968044
DOI: 10.1007/s00281-018-0692-y

Abstract

In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

Keywords: Acquired resistance; Cancer immunotherapy; Checkpoint inhibitors; Immune escape; Immune evasion.

PubMed Disclaimer

Cited by

VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA, Croteau W, Noelle RJ, Lines JL. ElTanbouly MA, et al. Semin Immunol. 2019 Apr;42:101308. doi: 10.1016/j.smim.2019.101308. Semin Immunol. 2019. PMID: 31604531 Free PMC article. Review.
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.
Xie X, Lv J, Zhu W, Tian C, Li J, Liu J, Zhou H, Sun C, Hu Z, Li X. Xie X, et al. Transl Oncol. 2022 Jan;15(1):101287. doi: 10.1016/j.tranon.2021.101287. Epub 2021 Nov 19. Transl Oncol. 2022. PMID: 34808461 Free PMC article.
Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles.
Liskova A, Samec M, Koklesova L, Brockmueller A, Zhai K, Abdellatif B, Siddiqui M, Biringer K, Kudela E, Pec M, Gadanec LK, Šudomová M, Hassan STS, Zulli A, Shakibaei M, Giordano FA, Büsselberg D, Golubnitschaja O, Kubatka P. Liskova A, et al. EPMA J. 2021 May 17;12(2):155-176. doi: 10.1007/s13167-021-00242-5. eCollection 2021 Jun. EPMA J. 2021. PMID: 34025826 Free PMC article. Review.
Proteomics to study cancer immunity and improve treatment.
Franciosa G, Kverneland AH, Jensen AWP, Donia M, Olsen JV. Franciosa G, et al. Semin Immunopathol. 2023 Mar;45(2):241-251. doi: 10.1007/s00281-022-00980-2. Epub 2023 Jan 4. Semin Immunopathol. 2023. PMID: 36598558 Free PMC article. Review.
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade.
Karan S, Jung E, Boone C, Steinmetz NF. Karan S, et al. Cancer Immunol Immunother. 2024 Feb 13;73(3):51. doi: 10.1007/s00262-024-03636-2. Cancer Immunol Immunother. 2024. PMID: 38349406 Free PMC article.

See all "Cited by" articles

References

1. Cell. 2017 Feb 9;168(4):707-723 - PubMed
1. Immunity. 2016 Jun 21;44(6):1255-69 - PubMed
1. Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed
1. N Engl J Med. 2014 Dec 4;371(23):2189-2199 - PubMed
1. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations

[1] Cell. 2017 Feb 9;168(4):707-723 - PubMed

[2] Cell. 2017 Feb 9;168(4):707-723 - PubMed

[3] Immunity. 2016 Jun 21;44(6):1255-69 - PubMed

[4] Immunity. 2016 Jun 21;44(6):1255-69 - PubMed

[5] Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed

[6] Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed

[7] N Engl J Med. 2014 Dec 4;371(23):2189-2199 - PubMed

[8] N Engl J Med. 2014 Dec 4;371(23):2189-2199 - PubMed

[9] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 - PubMed

[10] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Acquired resistance to cancer immunotherapy

Affiliations

Acquired resistance to cancer immunotherapy

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources